Skip to main content
Explore URMC
menu

Acute Myeloid Leukemia (AML): Intensive Chemotherapy with or without Glasdegib or AZA with or without Glasdegib

Research Question:
Does the drug Glasdegib help the survival of patients with Acute Myeloid Leukemia?

Basic Study Information

Purpose:
The purpose of this study is to determine if glasdegib is superior to placebo in combination with azacitidine or cytarabine and daunorubicin in prolonging overall survival in subjects with untreated AML.

Location: University of Rochester Medical Center
Study Reference #: ILEU18020

Lead Researcher (Principal Investigator)

Lead Researcher: Jane Liesveld, MD

Study Contact Information

Study Coordinator: Brandon DeLorme
Phone: (585) 275-5295
Email: Brandon_Delorme@URMC.Rochester.edu

Additional Study Details

Contact This Study

This field is required
This field is required
You must agree to be contacted to continue.

Return to Search